Time depended Bcl-2 inhibition might be useful for a targeted drug therapy
© Talaiezadeh et al. 2015
Received: 3 August 2015
Accepted: 8 October 2015
Published: 2 November 2015
Over expression of Bcl-2 is frequently observed in several types of cancers and it is one of the prognostic markers in breast cancer. The importance of the Bcl-2 protein as ideal therapeutic target is the dual role of inhibiting apoptosis and autophagy-mediated cell death. Thus, the bcl-2 targeting may be a strategy of choice to improve treatment efficacy and overcome drug resistance to cancer chemotherapy. For this reason, we designed the siRNA mediated silencing of the Bcl-2 gene in the MCF-7 breast cancer cell line.
The purpose of this research was to investigate the effective Bcl-2 gene silencing by our homemade siRNA, more than previous study. Our data demonstrated that specific inhibition of the Bcl-2 by siRNA induces approximately more than 90 % gene silencing.
MCF-7 Cell lines were treated by homemade Bcl-2siRNA for the first time and control siRNA that was transfected with nanoparticle. The cells harvested at 24, 48 and 72 h and transcription level of Bcl-2 was examined by Real Time -PCR analysis. The drug sensitivity was detected by using LDH assay test. Finally Anexin V-FITC test was performed for evaluation of apoptosis.
In the present study, results showed that targeting the specific sequence of the Bcl-2 by our homemade siRNA in the MCF7 cell line and its effect was more obvious in 24 h in contrast to 48 and 72 h.
However, we showed here a time dependent blocking of the bcl-2 transcript that might lead to cell dead due autophagy, and not necessarily to apoptosis.
When cell is able to overcome a number of failsafe mechanisms, including apoptotic and autophagic cell death, and is also able to induce oncogene activation and tumor suppressor inactivation, it is said that the cell is cancerous . Among women, breast cancer is the most frequently diagnosed cancer and the leading reason of cancer death, reported for 23 % of the total cancer cases and 14 % of the cancer deaths . It is the most prevalent cancer both in the developed and developing countries.
Its development process involves decreasing expression of apoptosis gene and overexpression of anti-apoptosis and the genes involving in inhibition of autophagy such as BAD and Bcl-2, respectively [3–5].
Overexpression of Bcl-2 is frequently observed in several types of cancer such as breast, lung, ovarian, melanoma cancers, and is often associated with unfavorable outcome [7–10]. So impairment of Bcl-2 gene expression is a hallmark of cancer and can result in resistance to chemotherapy [11, 12].
Apoptosis (self-killing) and autophagy (self-eating) are two self-destructive processes which have captured the attention of researchers over the last decades. While apoptosis includes the activation of catabolic enzymes leading to the destruction of cellular structures and organelles, autophagy is a slow, localized phenomenon which contains the sequestration of cytoplasmic constituents (including organelles and long-lived proteins) into double-membrane-bound vesicles or autophagosomes, which ultimately fuse with lysosomes for degradation [15, 16]. These pathways are two key signaling pathways employed by the cell in response to different inducers. The mechanisms of them are different, and involve basically diverse sets of regulatory and executioner molecules [17–19].
Bcl-2 suppress apoptosis by binding to Bax or Bak, and inhibit autophagy by binding to the protein Beclin 1, which is required for the initiation of autophagasome formation in autophagy [20–22]. Therefore, Bcl-2 not only functions as an anti-apoptotic protein, but also as an anti-autophagy protein via its inhibitory interaction with Beclin 1 .
So the crosstalk between apoptosis and autophagy is complex in nature, and sometimes inconsistent, but certainly acute to the overall fate of the cell .
It is proposed that functional blockage of the anti-apoptotic Bcl-2 gene could possibly change the balance of the apoptotic and autophagy machinery in tumor cells and sensitizes them to chemo and radiotherapy. Thus, targeting of Bcl-2 may be a strategy of choice to improve treatment efficacy and overcome drug resistance to cancer chemotherapy. Small interfering RNA (siRNA) is also a powerful tool to validate the targets of therapeutic drugs. RNAi is being explored as a powerful tool to inhibit the expression of genes involved in oncogenes and genes that are involved in angiogenesis, metastasis, survival, anti-apoptosis and resistance to chemotherapy [24, 25]. And it has shown great promise for many diseases such as cancer.
The silencing effect of siRNAs isn’t long-lived, since the siRNAs ultimately decay within the cell , and this can be an advantage because this method is used to increase the efficiency of chemotherapy which is done in a short period of time.
Synthetic siRNAs strongly inhibit expression of the target gene in mammalian cells when they are transfected into the cells by cationic liposomes .
Resistance to chemotherapeutic agents is a major factor confounding cancer treatment. siRNAs have been used to decrease the drug resistance of cells in vitro by inhibiting the expression of Bcl-2. The degree of siRNA-mediated gene silencing was consistent with other reports where antisense reagents of several types were used to target Bcl-2 [27–30].
The purpose of the study was to investigate the possibility of Bcl-2 gene silencing by our homemade siRNA.
As Bcl-2 is an effective target for gene silencing in MCF-7 breast cancer cells, this cell line was obtained from Pasteur Institute of Iran. And then was cultured in RPMI-1640 medium containing 10 % fetal bovine serum (FBS) and 1 % penicillin–streptomycin under standard culture conditions (37 °C, 95 % humidified air and 5 % CO2).
Transfection of siRNA
First, in six-well tissue culture plates containing 2 mL antibiotic-free normal growth medium supplemented with FBS, 2 × 105 cells per well were seeded. The cells were then Incubated at 37 °C in a CO2 Incubator until they were 60–80 % confluent (This takes 18–24 h). Then the siRNA duplex solution was then added directly to the dilute Transfection Reagent using a pipette and mixed gently by pipetting the solution up and down. The mixture were incubated at room temperature for 15–45 min, and washed with 2 mL of siRNA transfection medium.
For each transfection, 0.8 mL of siRNA transfection medium was added to each tube containing the siRNA transfection reagent mixture, and was mixed gently and covertly the mixture on to the washed cells. The cells were then incubated in a CO2 incubator at 37 °C for 5–7 h.
Total RNA extraction and cDNA synthesis
Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). According to manufacturer’s instructions and then was quantified by nanodrop.
cDNA synthesis was performed using BIONER cDNA Synthesis Kit. And then cDNA was verified by PCR using gene specific primers for GAPDH as an internal control.
The sequences of Real-Time reverse transcription-polymerase chain reaction amplification of Bcl-2, GAPDH cDNA, and Bcl-2 primers were (5′-GGAGAGTGCTGAAGATTGATG-3′), (5′-AGTCTACTTCCTCTGTGATGTTG-3′), for forward and reverse respectively.
GAPDH primers were (5´-AGGGCTGCTTTTAACTCTGGT-3´), (5´-CCCCACTTGATTTTGGAGGGA -3′) for forward and reverse respectively.
Analysis of apoptosis
To provide a comparative assay of apoptosis by Annexin V labeling, tumor cells (1 × 106) were treated with Bcl-2 siRNA for 24–72 h and then were harvested and washed with PBS. Cells were resuspended in binding buffer and stained with Annexin V and propidium iodide (PI) according to manufacturer’s protocol (Abcam Kit), control and treated cells were detected and quantified by FACS analysis.
Lactate dehydrogenase activity-based cytotoxicity Assays
Non-radioactive colorimetric assay is suitable for high-throughput quantification of cell death and cell lysis, based on measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells. To do this, we let the cells proliferate, and at the end of experiment, the cells were lysed by adding the lysis reagent supplied with the kit. Total released LDH was measured with the reaction mix from the kit, according to the manufacturer’s protocol (Cytotoxicity Detection Kit PLUS (LDH) Roch).
Statistical analysis was carried out by one-way ANOVA.In all other cases, the results from at least three individual experiments (n ≥ 3) were averaged to determine mean and statistically significant difference.
In combination with standard chemotherapy, treatment with siRNA can also decrease the chemo resistance of specific cancers, indicating the potential of siRNA therapy for treating many malignant diseases . Two strategies must be carefully considered to address safety concerns and to guarantee effective, successful treatment of human diseases are design and delivery for RNAi effector molecule . So screening candidate siRNA for homology with available sequence databases can, in principle, predict and avoid several off-target effects we had predicted that our desined siRNA has more than 80 % efficiency.
Delivery is probably the only biggest obstacle to the development of RNAi-based therapeutic agents. Liposomes are commonly used carriers, delivering the siRNA with better transfection efficiency and protecting it from degradation  Yano et al. have used such a liposome to show that anti-bcl-2 siRNA complexed with cationic lipid liposome had a strong antitumor activity when executed intravenously in the mouse model of liver metastasis . So in our study the cell line was transfected using siRNA Transfection Reagent (Santa Cruz Biotechnology, Inc), that is a cationic lipid which its components are the size of Nano particle that it cause more transfection efficiency.
Control siRNA (FluoresceinConjugate)-A is recommended for measuring transfection efficiency of cationic lipid based transfection reagents in cells, in order to determine the most suitable transfection reagent to utilize for RNAi studies.
Down regulation of Bcl-2 mRNA expression in MCF-7 breast cancer cells
Specific down regulation of Bcl-2 by antisense oligos or siRNA sensitizes cancer cells to chemotherapy or radiation therapy. Hence to inhibit the expression of Bcl-2, we applied siRNA to target directly the Bcl-2 transcript. We studied time-dependent down regulation of Bcl-2 and observed that Bcl-2 siRNA-induced down regulation of Bcl-2 mRNA, was started at 24 h after treatment but an unknown cause led to increase in gene expression of Bcl-2 in 48 h after transfection. Interestingly, most of the gene silencing of Bcl-2 was observed in 24 h after transfection of siRNA, and it is unlike the previous studies.
Down regulation of Bcl-2 mRNA level was observed after 48 h. Interestingly, after 72 h Bcl-2 gene expression level came back to normal level. Nevertheless, down regulation of Bcl-2 transcription level in 24 h was more than other periods.
LDH assay test showed no significant sign of cell death
LDH test indicated higher apoptosis in cell treated with siRNA in different times in contrast to controls but the results were not approved by statistical analysis (no data shown).
Bcl-2 siRNA decrease apoptosis cell death in MCF-7 cell line
We next evaluated programmed cell death mechanisms, including apoptosis. One of the earliest changes during apoptosis is translocation of the membrane phospholipid phosphatidyl serine from the inner leaflet of the membrane to the outer one. Therefore, phosphatidyl serine expression at the external membrane was investigated by the Annexin V assay [33, 34].
No increase in apoptosis was found in MCF-7 cell line treated with Bcl-2 siRNA evaluating by Annexin staining at 72 h. A time-dependent decrease in apoptosis of MCF-7 cell line was associated with down regulation of Bcl-2 mRNA. These findings suggest that apoptosis inhibition by down regulation of Bcl-2 might not play an important role in cell death, and that cell death was probably due autophagy.
We aimed here to appropriate blocking of the bcl-2 function as a potent apoptosis trigger by siRNA silencing. On transcription level we observed a time depended and significant decreasing of the bcl-2 mRNA. But this event was restricted for 24 h. However, in this sight of view, it could be the efficient time for appropriate drug therapy against chemotherapy resistant tumor cells. The other hallmark of the present study was the improvement of the idea that the bcl-2 blocking would not necessarily lead to apoptosis, but to autophagy, as will be discussed.
Bcl-2 protein interacts with Beclin 1 protein which is an autophagy factor, and Bcl-2 reduction causes Beclin 1 to release, which triggers autophagy. Apoptosis and autophagy are two separated mechanism. It has been reported that autophagy blocks apoptosis in some cases. To interpret our results, reduction in apoptosis after 24 h of treatment with siRNA is due to autophagy activation, and sudden reduction of apoptosis after 48 h in contrast to 24 and 72 h is probably because of anti-apoptosis characteristics of Bcl-2 gene, which results in apoptosis reduction.
We tried to illustrate conflicting results that observed at 48 h after transfection, but as many intracellular molecular mechanisms are still unknown furthermore, to clarify the relationship between different types of cell death, more study is needed, and must provide additional tools for analysis these processes.
Also an unfortunate irony of the revolution in understanding cancer as a genetic disease is that a single accepted treatment directly targets the products of the genes that are most frequently activated in human cancers without interfering with other pathways in human cancers . Although quite a lot of studies have been done on Bcl-2, there are numerous unclarified interactions partners which regulate its activities and connect it to a wide variety of cellular pathways.
Although our study confirmed the previous studies that Bcl-2 gene silencing doesn’t induce apoptosis [35, 36], it remains an ongoing mystery how the cells ‘decide’ to respond to siRNA by preferentially undergoing autophagy, and not apoptosis.
In conclusion, our results indicated the possibility of complete down regulation of the Bcl-2 mRNA level by novel designed Bcl-2 in the MCF-7 human breast cancer cells. But, the question remains whether the cell dead is due apoptosis or autophagy or even a combination of both pathways. However, studies at the molecular level on the interplay between autophagy and apoptosis are necessary. To explore the sensitization effects of gene silencing, Bcl-2 siRNA should also be combined with chemotherapeutic agent.
HG designed the project; AT participated in project; FJ carried out molecular genetic studies; AK drafted the manuscript.
We thank the Cancer, Petroleum and Environment Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran for supporting this work.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hahn W, Weinberg R. Rules for making human tumor cells. N Engl J Med. 2002;347:1593–603.View ArticlePubMedGoogle Scholar
- Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.View ArticlePubMedGoogle Scholar
- Yu B, Sun X, Shen H, Gao F, Fan Y, Sun Z. Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res. 2010;29:1–7.View ArticleGoogle Scholar
- Pattingre S, Tassa A, Qu X, Garuti R, Liang X, Mizushima N, Packer M, Schneider M, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927–39.View ArticlePubMedGoogle Scholar
- Maiuri M, Tasdemir E, Criollo A, Morselli E, Vicencio J, Carnuccio R, Kroemer G. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009;16:87–93.View ArticlePubMedGoogle Scholar
- Society AC. Breast cancer facts and figures 2013–2014. Atlanta: American Cancer Society; 2013.Google Scholar
- Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther. 2009;8:1421–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Walensky L. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ. 2006;13:1339–50.View ArticlePubMedGoogle Scholar
- Zhang H, Yousem S, Franklin W, Elder E, Landreneau R, Ferson P, Keenan R, Whiteside T, Levitt M. Differentiation and programmed cell deathrelated intermediate biomarkers for the development of non-small cell lung cancer: a pilot study. Hum Pathol. 1998;29:965–71.View ArticlePubMedGoogle Scholar
- Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 2002;16:1453–5.PubMedGoogle Scholar
- Adams J, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–37.PubMed CentralView ArticlePubMedGoogle Scholar
- Adams J, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–37.PubMed CentralView ArticlePubMedGoogle Scholar
- Edinger A, Thompson C. Defective autophagy leads to cancer. Cancer Cell. 2003;4:422–4.View ArticlePubMedGoogle Scholar
- Shamas-Din A, Kale J, Leber B, Andrews D. Mechanisms of action of bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5:a008714.PubMed CentralView ArticlePubMedGoogle Scholar
- Levine B, Klionsky D. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463–77.View ArticlePubMedGoogle Scholar
- Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 2011;278:403–13.View ArticlePubMedGoogle Scholar
- Danial N, Korsmeyer S. Cell death: critical control points. Cell. 2004;116:205–19.View ArticlePubMedGoogle Scholar
- Mizushima N, Klionsky D. Protein turnover via autophagy: implications for metabolism*. Annu Rev Nutr. 2007;27:19–40.View ArticlePubMedGoogle Scholar
- Uchiyama Y, Shibata M, Koike M, Yoshimura K, Sasaki M. Autophagy–physiology and pathophysiology. Histochem Cell Biol. 2008;129:407–20.PubMed CentralView ArticlePubMedGoogle Scholar
- Yip K, Reed J. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398–406.View ArticlePubMedGoogle Scholar
- Kuwana T, Newmeyer D. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol. 2003;15:691–9.View ArticlePubMedGoogle Scholar
- Eisenberg-Lerner A, Bialik S, Simon H, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009;16:966–75.View ArticlePubMedGoogle Scholar
- Stevenson M. Therapeutic potential of RNA interference. N Engl J Med. 2004;351:1772–7.View ArticlePubMedGoogle Scholar
- Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Exp Opin Ther Targ. 2008;12:637–45.View ArticleGoogle Scholar
- Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–8.View ArticlePubMedGoogle Scholar
- Biroccio A, Leonetti C, Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene. 2003;22:6579–88.View ArticlePubMedGoogle Scholar
- Lima R, Martins L, Guimaraes J, Sambade C, Vasconcelos M. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004;11:309–16.View ArticlePubMedGoogle Scholar
- Basma H, El-Refaey H, Sgagias M, Cowan K, Luo X, Cheng P. BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci. 2005;12:999–1011.View ArticlePubMedGoogle Scholar
- Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn E, Herold C, Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005;54:1298–308.PubMed CentralView ArticlePubMedGoogle Scholar
- Daniel H, Kim J, John J. Rossi: Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–84.View ArticleGoogle Scholar
- Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res. 2004;10:7721–6.View ArticlePubMedGoogle Scholar
- Lu L, Osmond D. Apoptosis during B lymphopoiesis in mouse bone marrow. J Immunol. 1997;158:5136–45.PubMedGoogle Scholar
- Akar U, Ozpolat O, Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res. 2007;5:241–9.View ArticlePubMedGoogle Scholar
- Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez B, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008;4:669.View ArticlePubMedGoogle Scholar
- Talaiezadeh A, Shahriari A, Tabandeh MR, Fathizadeh P, Mansouri S. Kinetic charachterization of lactate dehydrogenase in normal and malignant human breast tissues. Cancer Cell Int. 2015;15:9. doi: 10.1186/s12935-015-0171-7.